BNP predicts mortality of cardiovascular disease in patients with end-stage renal disease treated

Area of Science:

• Nephrology
• Cardiology
• Biomarkers

Context:

• Patients with end-stage renal disease (ESRD) face a substantially elevated risk of cardiovascular disease (CVD) mortality, estimated to be 20 times greater than the general population.
• Cardiovascular complications are a leading cause of death in individuals with chronic kidney disease (CKD).
• Natriuretic peptides, including type-B natriuretic peptide (BNP), are being investigated for their potential role in assessing cardiovascular risk.

Purpose:

• To investigate the prognostic value of type-B natriuretic peptide (BNP) as a marker for cardiovascular (CV) mortality in patients with end-stage renal disease (ESRD).

Summary:

• A study involving 53 ESRD patients on peritoneal dialysis, without baseline heart failure, assessed the predictive capability of BNP for CVD mortality.
• Survival probabilities were analyzed using Kaplan-Meier and log-rank tests based on BNP levels, with Cox proportional hazards analysis used for adjusted hazard ratios.
• Results indicated that BNP is a strong predictor of CVD mortality in ESRD patients, with higher BNP levels correlating with increased mortality risk.

Impact:

• Serum BNP measurement can serve as a valuable tool for stratifying cardiovascular risk in ESRD patients.
• These findings suggest that BNP levels can inform treatment adjustments to mitigate CVD mortality in this high-risk population.